Body Systems

Leukemia13 Results found

Studies recruiting participants:

An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Ph+ ALL

The purpose of this study is to compare the efficacy of the drugs ponatinib versus imatinib, administered as first-line therapy in combination with reduced-intensity chemotherapy, in participants with newly diagnosed Ph+ ALL, as measured by the minimal residual disease (MRD)-negative complete rem

Recruiting
Principal Investigator 
Yasser Abou Mourad
Body Locations and Systems 
Leukemia
Area 
Vancouver
Age 
18 and above

CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (CLIC-01)

The purpose of this study is to evaluate the safety, feasibility and efficacy of CLIC-1901 autologous anti-CD19 Chimeric Antigen Receptor T cells (CAR-T) cells for participants with relapsed/refractory CD19 positive (CD19+) Acute Lymphoblastic Leukemia (ALL) and non-Hodgkin's Lymphoma (NHL).

Recruiting
Principal Investigator 
Kevin Hay
Body Locations and Systems 
Leukemia
Area 
Vancouver
Age 
18-75

Closed for recruitment:

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication (FLT3-ITD) positive AML who are refractory to or have relapsed within 6 mont

Closed for Recruitment
Principal Investigator 
Donna E. Hogge
Body Locations and Systems 
Leukemia
Area 
Vancouver
Age 
18 and above

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) (HELIOS)

The purpose of the study is to determine if overall mortality is affected one year after a hematopoietic stem cell transplant (HCT) in patients given a vaccine to prevent cytomegalovirus (CMV).  Safety of ASP0113 in subjects undergoing allogeneic HCT will also be evaluated.

Closed for Recruitment
Principal Investigator 
Raewyn Broady
Body Locations and Systems 
Leukemia
Area 
Vancouver
Age 
18 and above